aTYR PHARMA INC (ATYR)

Every figure this model derived for ATYR, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 279,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 57,418,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 58,362,000 AssetsCurrent 2026-06-30
current liabilities 11,396,000 LiabilitiesCurrent 2026-06-30
equity 48,788,000 StockholdersEquity 2026-06-30
interest expense 71,000 InterestPaidNet 2026-06-30
ocf -54,540,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 190,000 RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31
sbc 4,966,000 AllocatedShareBasedCompensationExpense 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ATYR on one particular measure came for.

RatioValue
current ratio5.12
current ratio reported5.12
deferred revenue growth-84.94
dilution pct25.23
growth cv2.29
interest cover-899.41
revenue growth-19.15
revenue growth per share-35.44
rule of 40-33628.62

What to be careful about

What this model itself distrusts about ATYR's figures. Written by the derivation as it ran, not added afterwards.